PREVENTIVE ZINC SUPPLEMENTATION IN DEVELOPING COUNTRIES: IMPACT ON MORTALITY AND MORBIDITY DUE TO DIARRHEA, PNEUMONIA AND MALARIA

Related Articles

ACETYLCYSTEINE AND CARBOCYSTEINE FOR ACUTE UPPER AND LOWER RESPIRATORY TRACT INFECTIONS IN PAEDIATRIC PATIENTS WITHOUT CHRONIC BRONCHO-PULMONARY DISEASE

22/01/2013

PROPHYLACTIC DRUG MANAGEMENT FOR FEBRILE SEIZURES IN CHILDREN

22/01/2013

ZINC AS ADJUNCT TREATMENT IN INFANTS AGED BETWEEN 7 AND 120 DAYS WITH PROBABLE SERIOUS BACTERIAL INFECTION: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

22/01/2013

BMC Public Health. 2011 Apr 13;11 Suppl 3:S23.

Yakoob MY, Theodoratou E, Jabeen A, Imdad A, Eisele TP, Ferguson J, Jhass A,Rudan I, Campbell H, Black RE, Bhutta ZA.

Source: Division of Women & Child Health, TheAga KhanUniversity,Karachi,Pakistan.

BACKGROUND:

Zinc deficiency is commonly prevalent in children in developing countries and plays a role in decreased immunity and increased risk of infection. Preventive zinc supplementation in healthy children can reduce mortality due to common causes like diarrhea, pneumonia and malaria. The main objective was to determine all-cause mortality and cause-specific mortality and morbidity in children under five in developing countries for preventive zinc supplementation.

DATA SOURCES/ REVIEW METHODS:

A literature search was carried out on PubMed, the Cochrane Library and the WHO regional databases to identify RCTs on zinc supplementation for greater than 3 months in children less than 5 years of age in developing countries and its effect on mortality was analyzed.

RESULTS:

The effect of preventive zinc supplementation on mortality was given in eight trials, while cause specific mortality data was given in five of these eight trials. Zinc supplementation alone was associated with a statistically insignificant 9% (RR = 0.91; 95% CI: 0.82, 1.01) reduction in all cause mortality in the intervention group as compared to controls using a random effect model. The impact on diarrhea-specific mortality of zinc alone was a non-significant 18% reduction (RR = 0.82; 95% CI: 0.64, 1.05) and 15% for pneumonia-specific mortality (RR = 0.85; 95% CI: 0.65, 1.11). The incidence of diarrhea showed a 13% reduction with preventive zinc supplementation (RR = 0.87; 95% CI: 0.81, 0.94) and a 19% reduction in pneumonia morbidity (RR = 0.81; 95% CI: 0.73, 0.90). Keeping in mind the direction of effect of zinc supplementation in reducing diarrhea and pneumonia related morbidity and mortality; we considered all the outcomes for selection of effectiveness estimate for inclusion in the LiST model. After application of the CHERG rules with consideration to quality of evidence and rule # 6, we used the most conservative estimates as a surrogate for mortality. We, therefore, conclude that zinc supplementation in children is associated with a reduction in diarrhea mortality of 13% and pneumonia mortality of 15% for inclusion in the LiST tool. Preventive zinc supplementation had no effect on malaria specific mortality (RR = 0.90; 95% CI: 0.77, 1.06) or incidence of malaria (RR = 0.92; 95 % CI 0.82-1.04).

CONCLUSION:

Zinc supplementation results in reductions in diarrhea and pneumonia mortality.